Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abdulrahman I. Al Shaya"'
Autor:
Khalid Al Sulaiman, Hadeel A. Alkofide, Mashael E. AlFaifi, Sarah S. Aljohani, Abdullah F. Al Harthi, Rahaf A. Alqahtani, Ashwaq M. Alanazi, Lama H. Nazer, Abdulrahman I. Al Shaya, Ohoud Aljuhani
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 6, Pp 102094- (2024)
Background: Septic shock is associated with systemic inflammatory response, hemodynamic instability, impaired sympathetic control, and the development of multiorgan dysfunction that requires vasopressor or inotropic support. The regulation of immune
Externí odkaz:
https://doaj.org/article/b95975baf1824fa99f5a2e070118a084
Autor:
Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Meshal S. Alotaibi, Noura A. Alrakban, Ragia H. Ghoneim, Ramesh Vishwakarma, Abdulrahman I. Al Shaya, Shmeylan Al Harbi, Jawaher Gramish, Dahlia M. Almutairi, Ghada Alqannam, Faisal F. Alamri, Abdullah F. Alharthi, Mashael Alfaifi, Abdullah Al Amer, Abeer A. Alenazi, Norah Bin Aydan, Mai Alalawi, Khalid Al Sulaiman
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 7, Pp 1210-1218 (2023)
Background: Oseltamivir has been used as adjunctive therapy in the management of patients with COVID-19. However, the evidence about using oseltamivir in critically ill patients with severe COVID-19 remains scarce. This study aims to evaluate the eff
Externí odkaz:
https://doaj.org/article/06e3d4711b5747b583db96bbbf412425
Autor:
Ghazwa B. Korayem, Ohoud Aljuhani, Ali F. Altebainawi, Abdulrahman I. Al Shaya, Lina I. Alnajjar, Abdulrahman Alissa, Mohammed Aldhaeefi, Raed Kensara, Hessa Al Muqati, Abdulmohsen Alhuwahmel, Omar Alhuthaili, Ramesh Vishwakarma, Namareq Aldardeer, Khalid Eljaaly, Aisha Alharbi, Shmeylan Al Harbi, Abdulmalik Al Katheri, Abdulkareem M. Al Bekairy, Ahmed Aljedai, Khalid Al Sulaiman
Publikováno v:
International Journal of Infectious Diseases, Vol 122, Iss , Pp 252-259 (2022)
ABSTRACT: Objectives: Evidence supports tocilizumab (TCZ) benefit and safety in adult patients with severe COVID-19. However, its effectiveness in critically ill older adult patients remains questionable. Thus, the study aimed to evaluate the safety
Externí odkaz:
https://doaj.org/article/145f3c9134124608801970a63d78ac89
Autor:
Ohoud Aljuhani, Khalid Al Sulaiman, Adel Alshabasy, Khalid Eljaaly, Abdulrahman I. Al Shaya, Haytham Noureldeen, Mohammed Aboudeif, Bodoor Al Dosari, Amina Alkhalaf, Ghazwa B. Korayem, Muneera M. Aleissa, Hisham A. Badreldin, Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (
Externí odkaz:
https://doaj.org/article/c8d00252251f49ceb5ec2537a6f9c97e
Autor:
Khalid Al Sulaiman, Ohoud Aljuhani, Abdulrahman I. Al Shaya, Abdullah Kharbosh, Raed Kensara, Alhomaidi Al Guwairy, Aisha Alharbi, Rahmah Algarni, Shmeylan Al Harbi, Ramesh Vishwakarma, Ghazwa B. Korayem
Publikováno v:
Critical Care, Vol 25, Iss 1, Pp 1-8 (2021)
Abstract Background Zinc is a trace element that plays a role in stimulating innate and acquired immunity. The role of zinc in critically ill patients with COVID-19 remains unclear. This study aims to evaluate the efficacy and safety of zinc sulfate
Externí odkaz:
https://doaj.org/article/19d5ca74610a44708393596dd4f24ae9